The Pre-Heart Failure in Hypertension

Abstract

The objectives of this study were to detect pre-heart failure based on NT-proBNP in subjects with hypertension and to identify the risk factors for pre-heart failure. Research methods: We conducted a cross -sectional study between August and December 2022. This study was included 526 subjects with hypertension aged from 35- to 64 years, who had no clinical symptoms of heart failure. Cardiovascular risk factors were detected by clinical examinations and laboratory test. Hypertension was defined as systolic BP ≥ 130 mm Hg, diastolic BP ≥ 80 mm Hg, and/or receiving treatment with anti-hypertensive agents. NT-pro BNP determination was performed on an immunoassay analyzer (Getein 1100). An elevated NT-pro BNP was defined as a NT-pro BNP ≥ 125pg/ml. Pre-heart failure was based on elevated NT-pro BNPlevel. Ethical statement Research ethical permission was obtained from the Biomedical Ethics Committee of Mongolian National University of Medical Sciences. Research results: In total, 526 hypertensive subjects s aged 35-64 year enrolled in this study, of which, 243 (46.2%) were men and mean age was 52.5±7.7 years. The prevalence of pre-heart failure based on NT-pro BNP in women was non-significantly higher than in men(17.3% vs 14.0%, p= 0.297). The prevalence of pre-heart failure increased from 4.0% for men aged 35-44 years to 20.9% for men aged 55-64 years. Based on our logistic regression analysis, the likelihood of elevated NT-pro BNP in hypertensive subjects was independently associated with age(OR 2.18, 95%CI 1.51-3.14) and poor blood pressure control(OR 2.41, 95%CI 1.29-4.50). Conclusion: The present study showed that the overall prevalence of pre-heart failure in hypertensive subjects was 15.8% and increased with age. The poor blood pressure control and ageing were significant risk factors in the development pre-heart failure in subjects with hypertension.